Pulmonary Rehabilitation in Lymphangioleiomyomatosis

Status Completed

Clinical Trial Summary

Lymphangioleiomyomatosis (LAM) is a rare disease in which reduced exercise capacity is frequently present. The mechanisms applied are airflow obstruction, abnormal diffusion capacity and dynamic hyperinflation (DH).

Pulmonary rehabilitation (PR) has proved benefit in improving exercise tolerance, dyspnea, and quality of life in chronic obstructive pulmonary disease. There are no studies evaluating the impact of PR in patients with LAM.

The hypothesis under study is that PR determine improvement in exercise capacity, dyspnea, quality of life, muscle force, functional limitation and DH in these patients.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Lymphangioleiomyomatosis

Clinical Trial Details

NCT number	NCT02009241
Study type	Interventional
Source	University of Sao Paulo General Hospital
Contact
Status	Completed
Phase	N/A
Start date	November 2013
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01687179` - Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis	Phase 1
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed	`NCT00552955` - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Unknown status	`NCT00490789` - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM	Phase 2
Not yet recruiting	`NCT05087134` - Characterizing LAM With 11C-Choline PET/CT	Early Phase 1
Recruiting	`NCT05190627` - Effect of Loratadine in Lymphangioleiomyomatosis	Phase 2
Completed	`NCT05323370` - Lymphangioleiomyomatosis, a Study on Cathepsin K
Completed	`NCT02859194` - The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients	N/A
Completed	`NCT01353209` - Letrozole for Lymphangioleiomyomatosis	Phase 2
Completed	`NCT03253913` - Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial	Phase 2
Recruiting	`NCT02432560` - Safety and Durability of Sirolimus for Treatment of LAM
Completed	`NCT02061397` - Safety of Simvastatin in LAM and TSC	Phase 1/Phase 2
Active, not recruiting	`NCT01552434` - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Phase 1
Recruiting	`NCT04577937` - Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis	N/A
Completed	`NCT00005906` - Treatment With Octreotide in Patients With Lymphangioleiomyomatosis	Phase 2
Recruiting	`NCT01799538` - Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis	Phase 1/Phase 2
Completed	`NCT00989742` - Doxycycline In Lymphangioleiomyomatosis (LAM)	Phase 4
Recruiting	`NCT06160310` - Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Enrolling by invitation	`NCT05727852` - Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Completed	`NCT03131999` - LAM Pilot Study With Imatinib Mesylate	Phase 1/Phase 2